Akums Drugs and Pharmaceuticals saw its shares rise 8% to Rs 784.6 on its debut, despite a strong subscription rate of 63.44 times. Analysts recommend holding for long-term gains, highlighting the company's solid fundamentals and leading market position. The IPO funds will be used for debt repayment, working capital, and acquisitions.
